Day: May 30, 2024

Oslo, 30 May 2024  Prosafe has been issued a Conditional Letter of Intent (CLoI) for the Safe Boreas to provide gangway connected operations to support a project off the coast of Western Australia. The CLoI is conditional upon execution of a final contract. The firm duration of the contract linked to the CLoI is 15 months with up to six months of options. The Safe Boreas will mobilise from the North Sea within Q2 2025. Safe Boreas will undergo its five-yearly special periodic survey and other maintenance works prior to commencement of the contract. The value of the contract linked to the CLoI is approximately USD 75 million to USD 100 million depending on options. The Safe Boreas is one of the world’s most advanced and versatile semi-submersible DP-3 accommodation vessels and complies with stringent rules in Australia, Norway and UK....

VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (NYSE: FSM | TSX: FVI) is pleased to announce the publication of its sixth annual sustainability report which details the Company’s performance on key environmental, social, and governance (ESG) indicators during 2023. The report also includes dedicated sections on Fortuna’s sustainability management and initiatives at each of the Company’s operating mines as well as the contributions made within the countries that host our operations in the Latin America and West Africa regions. Also included is an ESG data section containing disclosure under sustainability accounting Standards Board (SASB) Metals and Mining Standard, the Task Force on Climate-Related Financial Disclosures Recommendations (TCFD), and the Global Reporting Initiative (GRI) standard. Jorge...

SHANGHAI, May 30, 2024 (GLOBE NEWSWIRE) — Hywin Holdings Ltd. (“Hywin”, or the “Company”) (NASDAQ: HYW) today announced that it has received a notification letter dated May 28, 2024 (the “Notice”) from the staff of the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the “Nasdaq”), indicating that the Company is not in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules as the closing bid price of the Company’s American depositary shares (“ADSs”) has been below US$1.00 per ADS for a period of 30 consecutive trading days. The Notice has no immediate effect on the listing or trading of the Company’s ADSs on Nasdaq. Pursuant to Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a compliance period of 180...

ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) —Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory Board Oculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRockOculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting held on May 29, 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST, including election of new members to its Board of...

Shareholders approved all agenda items and proposals of the Board of Directors Robert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of Directors Baruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory Board Oculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRockZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting held on May 29, 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST, including election of new members to its Board of...

Atos – Technology Rehearsal – Olympic and Paralympic Games Paris 2024Technology RehearsalPress Release Atos completes final Technology Rehearsal for the Olympic and Paralympic Games Paris 2024 Paris, France – May 30, 2024 – Atos today announces the successful completion of the final Technology Rehearsal prior to the Olympic and Paralympic Games Paris 2024. This last Technology Rehearsal took place from May 13 to 17 in different venues in Paris and other sites of the Olympic and Paralympic Games. Technology Rehearsals are designed to test how well IT policies and procedures and technology teams can handle real-life situations that may impact competitions. They also foster the team’s cohesion and collaboration, while giving each person a clear sense on how to make a difference. As the IT integration leader, Atos coordinated...

PRESS RELEASE                                         Share Buyback Transaction Details May 23 – May 29, 2024 Alphen aan den Rijn – May 30, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 143,963 of its own ordinary shares in the period from May 23, 2024, up to and including May 30, 2024, for €21.6 million and at an average share price of €149.83. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2024...

  Clinical study performed in 2022 now published in peer-reviewed Neurology and Therapy Further elaborates on bioequivalence demonstrated versus European listed drug Dormicum® Early onset can be expected thanks to early blood concentration of midazolam with ZEPIZURE® Low variability confirmed, a key advantage vs other forms of administration, such as intranasal   Dijon, France May 30, 2024 -1030 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, announces the publication of clinical data in the peer-reviewed journal Neurology and Therapy. Seizures require urgent treatment when they last longer than 5 minutes and when...

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion diagnostic products in China, jointly developing NGS-based CDx for Bayer’s growing portfolio of precision cancer therapies. “We are delighted to have established a companion diagnostics collaboration with Bayer, a global leader in the biopharmaceutical industry. Burning Rock is committed to the comprehensive development of companion diagnostics...